11.48

1.41% 0.1619

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $11.48, with a volume of 435.54K. It is up +1.41% in the last 24 hours and down -10.10% over the past month. Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Previous Close:

$11.32

Open:

$11.27

24h Volume:

435.54K

Relative Volume:

0.26

Market Cap:

$682.02M

Revenue:

$122.29M

Net Income/Loss:

$122.31M

P/E Ratio:

5.3307

EPS:

2.1539

Net Cash Flow:

$12.00M

1W Performance:

+0.00%

1M Performance:

-10.10%

6M Performance:

+33.64%

1Y Performance:

+21.74%

1-Day Range:

$11.18

$11.58

1-Week Range:

$10.81

$11.60

52-Week Range:

$7.16

$15.04

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(888) 958-1253

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	11.48	672.22M	122.29M	122.31M	12.00M	2.1539
VRTX Vertex Pharmaceuticals Inc	515.50	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.71	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.46	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.24	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.25	39.31B	5.76B	514.49M	1.10B	4.4813

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	BTIG Research	Buy
Jul-02-25	Initiated	H.C. Wainwright	Buy
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

Aug 15, 2026

Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily

Aug 15, 2026

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits

Aug 15, 2026

Aug 14, 2026

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan

Aug 14, 2026

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan

Aug 14, 2026

Aug 13, 2026

Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView

Aug 13, 2026

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga

Aug 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire

Aug 13, 2026

Aug 12, 2026

Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat

Aug 12, 2026

Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat

Aug 12, 2026

Aug 11, 2026

Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria

Aug 11, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review

Aug 11, 2026

Aug 10, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 10, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - natlawreview.com

Aug 10, 2026

Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat

Aug 10, 2026

HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - MarketBeat

Aug 10, 2026

Aug 09, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire

Aug 09, 2026

Aug 08, 2026

Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm

Aug 08, 2026

Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Aug 08, 2026

Aug 07, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aug 07, 2026